Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. (December 2013)

• Record Type: Journal Article
• Authors: Tanizaki, Hideaki; Nakahigashi, Kyoko; Miyachi, Yoshiki; Kabashima, Kenji
• Is Part Of: Journal of dermatological treatment. Volume 24:Number 6(2013:Dec.)
• Page Start: 477
• Page End: 480
• Publication Date: 2013-12
• Subjects: Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.3109/09546634.2013.789472
• Languages: English
• ISSNs: 0954-6634

Abstract

<abstract> <title /> <p> <italic>Background: </italic>H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses. Guidelines in Europe recommend increasing doses as second-line therapy; however, more supportive evidences for these guidelines are required to justify this management strategy. <italic>Methods: </italic>In this study, the authors evaluated the effect of conventional and double doses of fexofenadine HCl on CIU and on histamine-induced skin responses by iontophoresis using visual and laser Doppler imaging scales in healthy donors. <italic>Results: </italic>Cutaneous manifestations in CIU and histamine-induced flare and itch in healthy donors were attenuated more extensively by a double dose of fexofenadine HCl compared with a conventional dose. <italic>Conclusion: </italic>The above findings support the management strategy that increasing the dose of non-sedative antihistamines is the second-line treatment choice for refractory CIU even in Japanese populations.</p> </abstract>